These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 21480667)

  • 1. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
    Misra R; Sahoo SK
    Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
    Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
    Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy.
    Acharya S; Sahoo SK
    Biomaterials; 2011 Aug; 32(24):5643-62. PubMed ID: 21600647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.
    Ganta S; Amiji M
    Mol Pharm; 2009; 6(3):928-39. PubMed ID: 19278222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
    Zheng Z; Aojula H; Clarke D
    J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The study on reversing mechanism of multidrug resistance of K562/A02 cell line by curcumin and erythromycin].
    Chang HY; Pan KL; Ma FC; Jiao XY; Zhu HF; Liu JH; Huang Y; Cao YH
    Zhonghua Xue Ye Xue Za Zhi; 2006 Apr; 27(4):254-8. PubMed ID: 16875558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
    Ji BS; He L
    J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
    Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
    Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells.
    Li R; Wu R; Zhao L; Wu M; Yang L; Zou H
    ACS Nano; 2010 Mar; 4(3):1399-408. PubMed ID: 20148593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
    Shen J; Zhang W; Wu J; Zhu Y
    Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
    Arora A; Seth K; Kalra N; Shukla Y
    Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
    Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
    Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.